{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    65,
    66,
    67,
    68,
    69,
    70,
    71,
    72,
    73,
    95
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Day 1 \nTreatment"
      },
      {
        "id": "anchor_llm_1",
        "definition": "Study entry and the start of symptom assessment",
        "anchorType": "Day1",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "at study entry (‘Day 1’ symptom count starts from the first day of symptoms), plus the presence of select symptoms within 24 hours prior to Day 1."
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening \n \nDay"
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_4",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "every day"
      },
      {
        "id": "rep_daily_3",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Follow-up Period"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "4 hours post"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "24 hours after"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "2 hours post"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "4 days after"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P29D",
        "interval": "P1D",
        "minObservations": 29,
        "exitCondition": "Completion of Day 29",
        "sourceText": "Participant-reported symptom diary Daily through Day 29"
      },
      {
        "id": "rep_llm_2",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P29D",
        "interval": "P1D",
        "minObservations": 29,
        "exitCondition": "Completion of Day 29",
        "sourceText": "Participant-reported symptom reminder Daily through Day 29"
      },
      {
        "id": "rep_llm_3",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P4D",
        "interval": "P1D",
        "minObservations": 4,
        "exitCondition": "Completion of first 4 days after IMP administration",
        "sourceText": "the sentinel group will be contacted daily (in-person or by telephone) for the first 4 days after IMP administration"
      },
      {
        "id": "rep_llm_4",
        "type": "Daily",
        "startOffset": "P1D",
        "endOffset": "P1D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "Completion of Day 1 safety monitoring",
        "sourceText": "Telephone contact for safety monitoring Daily"
      },
      {
        "id": "rep_llm_5",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P1D",
        "interval": "PT24H",
        "minObservations": 2,
        "exitCondition": "Dosing of second participant in sentinel group",
        "sourceText": "At each site, there will be an interval of 24 hours after dosing of the first participant in the sentinel group before the next participant can be dosed."
      },
      {
        "id": "rep_llm_6",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "P1D",
        "interval": "P7D",
        "minObservations": 1,
        "exitCondition": "IMP administration",
        "sourceText": "Following screening, and no more than 7 days (‘Day 1’ symptom count starts from the first day of symptoms) from self-reported onset of COVID-19-related symptoms or measured fever, participants will receive a single dose of IMP."
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "TREATMENT",
          "INTENSIVE_FOLLOW_UP",
          "LIMITED_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 6",
          "Day 3",
          "End of Study",
          "Day 8",
          "Day 29",
          "Day 169",
          "Screening",
          "Day 366",
          "Day 15",
          "Day 457",
          "Day 1",
          "Day 85"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring discontinuation or withdraws consent', 'path': ['EARLY_DISCONTINUATION_VISIT', 'SAFETY_FOLLOW_UP']}, {'condition': 'If subject is lost to follow-up', 'path': ['SURVIVAL_STATUS_CHECK']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Serum Sample",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Diary",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Initial assessment performed once to determine eligibility prior to randomization."
      },
      {
        "activityId": "Symptom Onset Tracking",
        "executionType": "Single",
        "rationale": "Participants are monitored for symptom onset from baseline through Day 5 to define the early intervention analysis set."
      },
      {
        "activityId": "Primary Endpoint Event Monitoring",
        "executionType": "Single",
        "rationale": "Enrollment and data cut-off are conditional upon reaching a specific decision point of 43 confirmed primary endpoint events."
      },
      {
        "activityId": "Safety and Efficacy Assessments",
        "executionType": "Single",
        "rationale": "Standard Phase III design implies repeated measurements of safety and efficacy at scheduled study visits."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Visits noted P/H can be performed either in-person at clinical site or at home depending on the participant's clinical status.",
        "footnoteId": "fn_1",
        "structuredCondition": "location.choice(clinical_site, home) IF participant_status == 'eligible'",
        "appliesToActivityIds": [
          "Visits marked P/H"
        ],
        "sourceText": "a. Visits noted P/H can be performed either in-person at clinical site or at home depending on the p"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Perform if no documentation of SARS-CoV-2 infection available; tested locally.",
        "footnoteId": "fn_2",
        "structuredCondition": "procedure.perform IF NOT exists(SARS-CoV-2_infection_documentation)",
        "appliesToActivityIds": [
          "SARS-CoV-2 testing"
        ],
        "sourceText": "b. Perform if no documentation of SARS-CoV-2 infection available; tested locally."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. Assessment will be performed only for participants attending in-person visits.",
        "footnoteId": "fn_3",
        "structuredCondition": "procedure.perform IF visit_type == 'in-person'",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "sourceText": "c. Assessment will be performed only for participants attending in-person visits."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Height is recorded only at the screening visit.",
        "footnoteId": "fn_4",
        "structuredCondition": "procedure.perform IF visit == 'screening'",
        "appliesToActivityIds": [
          "Height"
        ],
        "sourceText": "d. Height is recorded only at the screening visit."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_after",
        "text": "e. Perform pre-dose and 15 minutes (+/- 5 minutes) after both injections are complete.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.pre_dose AND timing.post_dose(PT15M, window=PT5M)",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "timingConstraint": "PT15M",
        "sourceText": "e. Perform pre-dose and 15 minutes (+/- 5 minutes) after both injections are complete."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_at",
        "text": "f. Perform pre-dose on Day 1.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.pre_dose IF day == 1",
        "appliesToActivityIds": [
          "Assessment"
        ],
        "sourceText": "f. Perform pre-dose on Day 1."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_at",
        "text": "h. Urine pregnancy test (local laboratory) at screening. Perform another urine test on Day 1 if screening test was performed on Day -1.",
        "footnoteId": "fn_8",
        "structuredCondition": "procedure.perform IF visit == 'screening' OR (visit == 'Day 1' AND screening_test_date == 'Day -1')",
        "appliesToActivityIds": [
          "Urine pregnancy test"
        ],
        "sourceText": "h. Urine pregnancy test (local laboratory) at screening. Perform another urine test on Day 1 if scre"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "i. Urine pregnancy test (local laboratory).",
        "footnoteId": "fn_9",
        "structuredCondition": "lab_type == 'local'",
        "appliesToActivityIds": [
          "Urine pregnancy test"
        ],
        "sourceText": "i. Urine pregnancy test (local laboratory)."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_at",
        "text": "j. Participants will report COVID-19-related symptoms daily in an electronic device, starting pre-dose and post-dose on Day 1.",
        "footnoteId": "fn_10",
        "structuredCondition": "frequency.daily START timing.pre_dose(Day 1)",
        "appliesToActivityIds": [
          "COVID-19-related symptoms reporting"
        ],
        "sourceText": "j. Participants will report COVID-19-related symptoms daily in an electronic device, starting pre-do"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Composite of Severe COVID-19 or Death",
        "endpointType": "Primary",
        "inputs": [
          "fever",
          "cough",
          "tachypnea",
          "dyspnea",
          "lung infiltrates",
          "SpO2",
          "respiratory distress",
          "WHO Clinical Progression Scale score",
          "death_date",
          "randomization_date"
        ],
        "timeWindow": {
          "reference": "Day 1 (IMP administration)",
          "duration": "P28D"
        },
        "algorithm": "IF (death_from_any_cause == TRUE AND event_day <= 29) OR ((pneumonia == TRUE OR hypoxemia == TRUE) AND WHO_score >= 5 AND event_day <= 29) THEN 1 ELSE 0",
        "successCriteria": "Relative Risk Reduction (RRR) > 0 calculated as 1 - Relative Risk",
        "sourceText": "The primary efficacy endpoint is a composite of either severe COVID-19 or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypne"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Death from any cause or hospitalization for COVID-19 complications or sequelae",
        "variableType": "Composite",
        "sourceVariables": [
          "Death date",
          "Hospitalization date",
          "Hospitalization reason"
        ],
        "derivationRule": "Binary outcome (Yes/No) if either death or hospitalization for COVID-19 complications occurs between Day 1 and Day 169",
        "baselineDefinition": "Day 1 (Post-dose period start)",
        "baselineVisit": "Day 1",
        "analysisWindow": "Day 1 to Day 169",
        "imputationRule": "Not specified in text",
        "unit": "Binary"
      },
      {
        "id": "dv_2",
        "name": "Time to death from any cause or first hospitalization for COVID-19 complications or sequelae",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of IMP administration",
          "Date of death",
          "Date of hospitalization"
        ],
        "derivationRule": "min(Date of death, Date of first hospitalization) - Date of IMP administration + 1",
        "baselineDefinition": "Date of IMP administration (Day 1)",
        "baselineVisit": "Day 1",
        "analysisWindow": "Day 1 to Day 169",
        "imputationRule": "Censoring at Day 169 or last known follow-up",
        "unit": "Days"
      },
      {
        "id": "dv_3",
        "name": "Relative Risk Reduction (RRR) of Key Secondary Endpoint",
        "variableType": "Custom",
        "sourceVariables": [
          "Incidence in AZD7442 group",
          "Incidence in Placebo group"
        ],
        "derivationRule": "(1 - Relative Risk) * 100",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "N/A",
        "analysisWindow": "Day 169",
        "imputationRule": "Not specified in text",
        "unit": "%"
      },
      {
        "id": "dv_4",
        "name": "Proportion of participants with respiratory failure",
        "variableType": "Categorical",
        "sourceVariables": [
          "Mechanical ventilation status",
          "ECMO status",
          "Non-invasive ventilation status",
          "High flow cannula oxygen delivery status"
        ],
        "derivationRule": "Binary outcome (Yes/No) if any of the source requirements are met through Day 29",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "N/A",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Not specified in text",
        "unit": "Proportion"
      },
      {
        "id": "dv_5",
        "name": "Progression of COVID-19-associated symptoms",
        "variableType": "Categorical",
        "sourceVariables": [
          "Participant-reported symptom diary entry",
          "Post-dose symptom status"
        ],
        "derivationRule": "Binary outcome (Yes/No) if one or more symptoms progress to a worse status than recorded in the diary entry prior to start of IMP",
        "baselineDefinition": "Last symptom diary entry prior to start of AZD7442 or placebo",
        "baselineVisit": "Pre-dose Day 1",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Not specified in text",
        "unit": "Proportion"
      },
      {
        "id": "dv_6",
        "name": "Time to undetectable SARS-CoV-2",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "SARS-CoV-2 viral load",
          "Date of IMP administration"
        ],
        "derivationRule": "Date of first undetectable sample - Date of IMP administration + 1",
        "baselineDefinition": "Date of IMP administration (Day 1)",
        "baselineVisit": "Day 1",
        "analysisWindow": "Through Day 29",
        "imputationRule": "Kaplan-Meier censoring",
        "unit": "Days"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Treatment",
        "Intensive Follow Up",
        "Limited Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Intensive Follow Up",
          "trigger": "Progress to Intensive Follow Up"
        },
        {
          "fromState": "Intensive Follow Up",
          "toState": "Limited Follow Up",
          "trigger": "Progress to Limited Follow Up"
        },
        {
          "fromState": "Limited Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Treatment": "TREATMENT",
        "Intensive Follow Up": "INTENSIVE_FOLLOW_UP",
        "Limited Follow Up": "LIMITED_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "AZD7442",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Investigational Medicinal Product (IMP)"
          }
        ],
        "durationDescription": "Single dose"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Matching placebo"
          }
        ],
        "durationDescription": "Single dose"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_6",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Following screening, and no more than 7 days (‘Day 1’ symptom count starts from the first day of symptoms) from self-reported onset of COVID-19-related symptoms or measured fever, participants will re"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "CONFIDENTIAL AND PROPRIETARY9 of 115 LIST OF TABLES"
      },
      {
        "id": "visit_12",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "End of Study Definition A participant is considered to have completed the study if he/she has completed all stages of the study, including the last scheduled procedure shown in the SoA (Table 1 for Co"
      },
      {
        "id": "visit_13",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Increased supplemental oxygen requirement (only for participants on baseline supplemental oxygen) 5"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "negative pregnancy test result at Visit 1 and during the study as in the SoA (Table 1 for Cohort 1 and Table 2 for Cohort 2)."
      },
      {
        "id": "visit_4",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Persons aged 65 years and older at randomization x Persons aged < 65 years and having at least one of the following conditions:"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Day 2 (Sentinel Group Only)",
        "targetDay": 2,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 3,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Day 3 (Sentinel Group Only)",
        "targetDay": 3,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 4,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Day 4 (Sentinel Group Only)",
        "targetDay": 4,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 5,
        "targetWeek": 1,
        "epoch": "Intensive Follow-up"
      },
      {
        "id": "visit_11",
        "visitName": "Day 6",
        "targetDay": 6,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "If evidence of injection site reaction persists at the Day 6 visit, the injection site will be rechecked at each visit until no evidence of an active reaction remains. r The first 20 participants dose"
      },
      {
        "id": "visit_5",
        "visitName": "Day 8",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "epoch": "Intensive Follow-up",
        "sourceText": "group’s safety data through Day 8 has been reviewed by the DSMB in order to provide a recommendation to continue or to halt dosing of additional participants. Participants will be enrolled into one of"
      },
      {
        "id": "visit_10",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "Mid-turbinate nasal swab is tested centrally. Sequencing applies to nasal swabs collected through Day 15. n Pre-dose sample and post-dose sample (ie, samples obtained prior to and upon completion of I"
      },
      {
        "id": "visit_8",
        "visitName": "Day 29",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Intensive Follow-up",
        "sourceText": "or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, AND lung infiltrates) or hypoxemia (SpO2 < 90% in room a"
      },
      {
        "id": "visit_15",
        "visitName": "Day 30",
        "targetDay": 30,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "appropriate that they can discuss with the investigator and others after Day 30 so as to make an informed choice. The following considerations apply: x"
      },
      {
        "id": "visit_9",
        "visitName": "Day 169",
        "targetDay": 169,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "events have been confirmed in the primary analysis population. A Day 169 analysis will be conducted when all participants have been followed through Day 169. A final analysis will be conducted when al"
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Follow-up, and Reporting ........................................................................... 82 Appendix C Handling of Human Biological Samples ................................................"
      },
      {
        "id": "visit_7",
        "visitName": "Day 457",
        "targetDay": 457,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "epoch": "Limited Follow-up",
        "sourceText": "28 days of intensive follow-up, followed by limited follow-up through Day 457. Disclosure Statement: This is a parallel-group treatment study with 2 arms that are double-blind."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified blocked randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Time from symptom onset",
          "categories": [
            "≤ 5 days",
            "> 5 days"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Risk of progression to severe COVID-19",
          "categories": [
            "High-risk",
            "Low-risk"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Clinical Study Protocol - 7.0 \nAstraZeneca \nAZD7442 - D8851C00001 \n \nCONFIDENTIAL AND PROPRIETARY12 of 115 \n \nADA Anti-drug-antibody; AE Adverse event; AESI Adverse event of special interest; AUC Area"
    }
  }
}